[S02DA03, antipyrine, The metabolism of Antipyrine can be decreased when combined with Moxifloxacin.]
[A02BX02, sucralfate, Sucralfate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01CA16, sulbenicillin, The serum concentration of Moxifloxacin can be increased when it is combined with Sulbenicillin.]
[J01EC02, sulfadiazine, The therapeutic efficacy of Sulfadiazine can be increased when used in combination with Moxifloxacin.]
[J01EC01, sulfamethoxazole, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Moxifloxacin.]
[S01AB02, sulfisoxazole, The therapeutic efficacy of Sulfisoxazole can be increased when used in combination with Moxifloxacin.]
[M01AB02, sulindac, Sulindac may increase the neuroexcitatory activities of Moxifloxacin.]
[N05AL01, sulpiride, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Sulpiride.]
[A10BB04, glibornuride, The therapeutic efficacy of Glibornuride can be increased when used in combination with Moxifloxacin.]
[A10BC01, glymidine, The therapeutic efficacy of Glymidine can be increased when used in combination with Moxifloxacin.]
[M01AX04, apazone, Azapropazone may increase the neuroexcitatory activities of Moxifloxacin.]
[L01BB02, mercaptopurine, The metabolism of Mercaptopurine can be decreased when combined with Moxifloxacin.]
[N06DA01, tacrine, The metabolism of Tacrine can be decreased when combined with Moxifloxacin.]
[J01CA15, talampicillin, The serum concentration of Moxifloxacin can be increased when it is combined with Talampicillin.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Moxifloxacin.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Moxifloxacin.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Tetrabenazine.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Moxifloxacin is combined with Tetracaine.]
[N05AE05, lurasidone, The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Moxifloxacin.]
[N04BC07, apomorphine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Moxifloxacin.]
[R03DA07, theobromine, The metabolism of Theobromine can be decreased when combined with Moxifloxacin.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Moxifloxacin.]
[P02CA02, thiabendazole, The metabolism of Thiabendazole can be decreased when combined with Moxifloxacin.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Eribulin is combined with Moxifloxacin.]
[N05AC02, thioridazine, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Thioridazine.]
[N05AF04, thiothixene, The metabolism of Thiothixene can be decreased when combined with Moxifloxacin.]
[B03AB03, sodium ironedetate, Sodium feredetate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01CA13, ticarcillin, The serum concentration of Moxifloxacin can be increased when it is combined with Ticarcillin.]
[S01ED01, timolol, The risk or severity of QTc prolongation can be increased when Timolol is combined with Moxifloxacin.]
[A10BB05, tolazamide, The therapeutic efficacy of Tolazamide can be increased when used in combination with Moxifloxacin.]
[V04CA01, tolbutamide, The therapeutic efficacy of Tolbutamide can be increased when used in combination with Moxifloxacin.]
[M02AA21, tolmetin, Tolmetin may increase the neuroexcitatory activities of Moxifloxacin.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Moxifloxacin.]
[S01BA05, triamcinolone, The risk or severity of tendinopathy can be increased when Triamcinolone is combined with Moxifloxacin.]
[C03DB02, triamterene, The metabolism of Triamterene can be decreased when combined with Moxifloxacin.]
[N05AB06, trifluoperazine, The metabolism of Trifluoperazine can be decreased when combined with Moxifloxacin.]
[D07AC02, fluclorolone, The risk or severity of tendinopathy can be increased when Fluclorolone is combined with Moxifloxacin.]
[R03BA07, mometasone, The risk or severity of tendinopathy can be increased when Mometasone is combined with Moxifloxacin.]
[A03AA05, trimebutine, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Moxifloxacin.]
[R06AD01, trimeprazine, The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Moxifloxacin.]
[N03AC02, trimethadione, The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Moxifloxacin.]
[N06AA06, trimipramine, The risk or severity of QTc prolongation can be increased when Trimipramine is combined with Moxifloxacin.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Moxifloxacin.]
[R03DX07, roflumilast, The serum concentration of Roflumilast can be increased when it is combined with Moxifloxacin.]
[L01EX04, vandetanib, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Vandetanib.]
[A10BH05, linagliptin, The therapeutic efficacy of Linagliptin can be increased when used in combination with Moxifloxacin.]
[J05AG05, rilpivirine, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Moxifloxacin.]
[N03AX21, ezogabine, The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Moxifloxacin.]
[R03AC18, indacaterol, The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Moxifloxacin.]
[C08DA01, verapamil, The metabolism of Verapamil can be decreased when combined with Moxifloxacin.]
[B01AA03, warfarin, The therapeutic efficacy of Warfarin can be increased when used in combination with Moxifloxacin.]
[N05AF05, zuclopenthixol, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Zuclopenthixol.]
[L01EC01, vemurafenib, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Vemurafenib.]
[L01ED01, crizotinib, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Crizotinib.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Moxifloxacin.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Ziprasidone.]
[N02BA01, aspirin, Acetylsalicylic acid may increase the neuroexcitatory activities of Moxifloxacin.]
[G04BD07, tolterodine, The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Moxifloxacin.]
[J02AC03, voriconazole, The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Moxifloxacin.]
[S01FA01, atropine, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Atropine.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Moxifloxacin.]
[H02AB11, prednylidene, The risk or severity of tendinopathy can be increased when Prednylidene is combined with Moxifloxacin.]
[L04AX01, azathioprine, The metabolism of Azathioprine can be decreased when combined with Moxifloxacin.]
[J01CA09, azlocillin, The serum concentration of Moxifloxacin can be increased when it is combined with Azlocillin.]
[A08AA11, lorcaserin, The metabolism of Lorcaserin can be decreased when combined with Moxifloxacin.]
[G04BD12, mirabegron, The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Moxifloxacin.]
[A02AA05, magnesium silicate, Magnesium silicate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[H02AA01, aldosterone, The risk or severity of tendinopathy can be increased when Aldosterone is combined with Moxifloxacin.]
[J05AE04, nelfinavir, The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Moxifloxacin.]
[L01AA09, bendamustine, The metabolism of Bendamustine can be decreased when combined with Moxifloxacin.]
[N04BD02, rasagiline, The metabolism of Rasagiline can be decreased when combined with Moxifloxacin.]
[N03AX22, perampanel, The metabolism of Perampanel can be decreased when combined with Moxifloxacin.]
[N02CC03, zolmitriptan, The metabolism of Zolmitriptan can be decreased when combined with Moxifloxacin.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Moxifloxacin.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Bedaquiline.]
[C04AX11, bencyclane, The risk or severity of QTc prolongation can be increased when Bencyclane is combined with Moxifloxacin.]
[A10BH04, alogliptin, The therapeutic efficacy of Alogliptin can be increased when used in combination with Moxifloxacin.]
[L04AX06, pomalidomide, The metabolism of Pomalidomide can be decreased when combined with Moxifloxacin.]
[N02BA10, benorilate, Benorilate may increase the neuroexcitatory activities of Moxifloxacin.]
[A10BK02, canagliflozin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Moxifloxacin.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Gemifloxacin.]
[A12CC09, magnesium orotate, Magnesium orotate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Moxifloxacin.]
[A10AE05, insulin detemir, The therapeutic efficacy of Insulin detemir can be increased when used in combination with Moxifloxacin.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Moxifloxacin is combined with Benzocaine.]
[A10BX05, pramlintide, The therapeutic efficacy of Pramlintide can be increased when used in combination with Moxifloxacin.]
[M01AH01, celecoxib, Celecoxib may increase the neuroexcitatory activities of Moxifloxacin.]
[A12CC05, magnesium aspartate, Magnesium aspartate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N04AC01, benztropine, The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Moxifloxacin.]
[L01EC02, dabrafenib, The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Moxifloxacin.]
[R02AX03, benzydamine, Benzydamine may increase the neuroexcitatory activities of Moxifloxacin.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Moxifloxacin is combined with Benzyl alcohol.]
[B03AB04, ferric hydroxide, Ferric hydroxide can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[C08EA02, bepridil, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Bepridil.]
[A10BJ03, lixisenatide, The therapeutic efficacy of Lixisenatide can be increased when used in combination with Moxifloxacin.]
[V03AE05, sucroferric oxyhydroxide, Iron sucrose can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A10BK01, dapagliflozin, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Moxifloxacin.]
[N05CH03, tasimelteon, The metabolism of Tasimelteon can be decreased when combined with Moxifloxacin.]
[L04AA32, apremilast, The metabolism of Apremilast can be decreased when combined with Moxifloxacin.]
[S03BA03, betamethasone, The risk or severity of tendinopathy can be increased when Betamethasone is combined with Moxifloxacin.]
[S01ED02, betaxolol, The metabolism of Betaxolol can be decreased when combined with Moxifloxacin.]
[A10BJ04, albiglutide, The therapeutic efficacy of Albiglutide can be increased when used in combination with Moxifloxacin.]
[L01ED02, ceritinib, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Ceritinib.]
[A03BA03, hyoscyamine, The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Moxifloxacin.]
[B01AA07, acenocoumarol, The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Moxifloxacin.]
[A10BK03, empagliflozin, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Moxifloxacin.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Moxifloxacin.]
[A16AX10, eliglustat, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Eliglustat.]
[A10BJ05, dulaglutide, The therapeutic efficacy of Dulaglutide can be increased when used in combination with Moxifloxacin.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Moxifloxacin.]
[V03AE08, ferric citrate, Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B01AA01, dicumarol, The therapeutic efficacy of Dicoumarol can be increased when used in combination with Moxifloxacin.]
[N06AX11, mirtazapine, The metabolism of Mirtazapine can be decreased when combined with Moxifloxacin.]
[L01EX08, lenvatinib, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Lenvatinib.]
[L01XH03, panobinostat, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Panobinostat.]
[N02BE01, acetaminophen, The metabolism of Acetaminophen can be decreased when combined with Moxifloxacin.]
[B01AA11, tioclomarol, The therapeutic efficacy of Tioclomarol can be increased when used in combination with Moxifloxacin.]
[C01EB17, ivabradine, Ivabradine may increase the QTc-prolonging activities of Moxifloxacin.]
[A06AD03, magnesium peroxide, Magnesium peroxide can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A10BF01, acarbose, The therapeutic efficacy of Acarbose can be increased when used in combination with Moxifloxacin.]
[M02AA25, aceclofenac, Aceclofenac may increase the neuroexcitatory activities of Moxifloxacin.]
[M01AB11, acemetacin, Acemetacin may increase the neuroexcitatory activities of Moxifloxacin.]
[A10AE06, insulin degludec, The therapeutic efficacy of Insulin degludec can be increased when used in combination with Moxifloxacin.]
[A10BB31, acetohexamide, The therapeutic efficacy of Acetohexamide can be increased when used in combination with Moxifloxacin.]
[G04CA01, alfuzosin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Moxifloxacin.]
[M01AE16, alminoprofen, Alminoprofen may increase the neuroexcitatory activities of Moxifloxacin.]
[N05BA08, bromazepam, The metabolism of Bromazepam can be decreased when combined with Moxifloxacin.]
[N04BC01, bromocriptine, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Moxifloxacin.]
[A02AD05, aluminum magnesium silicate, Almasilate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02AB03, aluminum phosphate, Aluminium phosphate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Moxifloxacin.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Moxifloxacin is combined with Levobupivacaine.]
[C07AA19, bupranolol, The risk or severity of QTc prolongation can be increased when Bupranolol is combined with Moxifloxacin.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Buserelin is combined with Moxifloxacin.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Arsenic trioxide.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Artemether.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Moxifloxacin.]
[S01GX07, azelastine, The metabolism of Azelastine can be decreased when combined with Moxifloxacin.]
[J01CE04, azidocillin, The serum concentration of Moxifloxacin can be increased when it is combined with Azidocillin.]
[L01XK03, rucaparib, The metabolism of Rucaparib can be decreased when combined with Moxifloxacin.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Moxifloxacin.]
[J01CA06, bacampicillin, The serum concentration of Moxifloxacin can be increased when it is combined with Bacampicillin.]
[L01EF02, ribociclib, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Ribociclib.]
[A07EC04, balsalazide, Balsalazide may increase the neuroexcitatory activities of Moxifloxacin.]
[R03DA08, bamifylline, The metabolism of Bamifylline can be decreased when combined with Moxifloxacin.]
[N07XX16, deutetrabenazine, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Moxifloxacin.]
[N06BC01, caffeine, The metabolism of Caffeine can be decreased when combined with Moxifloxacin.]
[A10BX06, benfluorex, The therapeutic efficacy of Benfluorex can be increased when used in combination with Moxifloxacin.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Moxifloxacin is combined with Oxybuprocaine.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Moxifloxacin.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Moxifloxacin.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Moxifloxacin.]
[J05AG03, efavirenz, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Efavirenz.]
[R03BA02, budesonide, The risk or severity of tendinopathy can be increased when Budesonide is combined with Moxifloxacin.]
[M01AB07, bumadizone, Bumadizone may increase the neuroexcitatory activities of Moxifloxacin.]
[N06AA15, butriptyline, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Butriptyline.]
[C01AA02, acetyldigoxins, The risk or severity of QTc prolongation can be increased when Acetyldigoxin is combined with Moxifloxacin.]
[A10BJ06, semaglutide, The therapeutic efficacy of Semaglutide can be increased when used in combination with Moxifloxacin.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Moxifloxacin is combined with Capsaicin.]
[A10BK04, ertugliflozin, The therapeutic efficacy of Ertugliflozin can be increased when used in combination with Moxifloxacin.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Moxifloxacin.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Macimorelin.]
[J01CA03, carbenicillin, The serum concentration of Moxifloxacin can be increased when it is combined with Carbenicillin.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Carbinoxamine.]
[C07AG02, carvedilol, The metabolism of Carvedilol can be decreased when combined with Moxifloxacin.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Encorafenib.]
[L01EE03, binimetinib, The metabolism of Binimetinib can be decreased when combined with Moxifloxacin.]
[C07AB08, celiprolol, The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Moxifloxacin.]
[L01XX62, ivosidenib, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Ivosidenib.]
[N03AX17, stiripentol, The metabolism of Stiripentol can be decreased when combined with Moxifloxacin.]
[S01GX12, cetirizine, The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Moxifloxacin.]
[A10BB06, carbutamide, The therapeutic efficacy of Carbutamide can be increased when used in combination with Moxifloxacin.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Moxifloxacin is combined with Chloroprocaine.]
[M01AC05, lornoxicam, Lornoxicam may increase the neuroexcitatory activities of Moxifloxacin.]
[R03DA02, oxtriphylline, The metabolism of Oxtriphylline can be decreased when combined with Moxifloxacin.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Inotersen is combined with Moxifloxacin.]
[L01AD01, carmustine, The metabolism of Carmustine can be decreased when combined with Moxifloxacin.]
[L01EX13, gilteritinib, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Gilteritinib.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Amifampridine.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Cibenzoline is combined with Moxifloxacin.]
[B01AC23, cilostazol, The metabolism of Cilostazol can be decreased when combined with Moxifloxacin.]
[P02BX04, triclabendazole, The metabolism of Triclabendazole can be decreased when combined with Moxifloxacin.]
[J01FA09, clarithromycin, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Clarithromycin.]
[H02AB14, cloprednol, The risk or severity of tendinopathy can be increased when Cloprednol is combined with Moxifloxacin.]
[V03AE07, calcium acetate, Calcium acetate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A12CC06, magnesium lactate, Magnesium lactate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V03AE02, sevelamer, Sevelamer can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[H02AB17, cortivazol, The risk or severity of tendinopathy can be increased when Cortivazol is combined with Moxifloxacin.]
[J01CF03, methicillin, The serum concentration of Moxifloxacin can be increased when it is combined with Meticillin.]
[C03BX03, cicletanine, The risk or severity of QTc prolongation can be increased when Cicletanine is combined with Moxifloxacin.]
[M03BX08, cyclobenzaprine, The metabolism of Cyclobenzaprine can be decreased when combined with Moxifloxacin.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Entrectinib.]
[N07XX11, pitolisant, Moxifloxacin may increase the QTc-prolonging activities of Pitolisant.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Moxifloxacin.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Moxifloxacin.]
[A10AE03, insulin, regular, pork, The therapeutic efficacy of Insulin pork can be increased when used in combination with Moxifloxacin.]
[H02AB13, deflazacort, The risk or severity of tendinopathy can be increased when Deflazacort is combined with Moxifloxacin.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Moxifloxacin.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Dexchlorpheniramine.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Moxifloxacin.]
[N02CC07, frovatriptan, The metabolism of Frovatriptan can be decreased when combined with Moxifloxacin.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Moxifloxacin.]
[M01AH02, rofecoxib, The metabolism of Rofecoxib can be decreased when combined with Moxifloxacin.]
[C01BD07, dronedarone, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Dronedarone.]
[V03AE03, lanthanum carbonate, Lanthanum carbonate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Moxifloxacin.]
[D07XB03, fluprednidene, The risk or severity of tendinopathy can be increased when Fluprednidene is combined with Moxifloxacin.]
[M01AC04, droxicam, Droxicam may increase the neuroexcitatory activities of Moxifloxacin.]
[M02AA27, dexketoprofen, Dexketoprofen may increase the neuroexcitatory activities of Moxifloxacin.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Moxifloxacin is combined with Dyclonine.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Ebastine is combined with Moxifloxacin.]
[J05AX29, fostemsavir, The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Moxifloxacin.]
[P01BA01, chloroquine, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Chloroquine.]
[R06AB04, chlorpheniramine, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Chlorpromazine.]
[A10BB02, chlorpropamide, The therapeutic efficacy of Chlorpropamide can be increased when used in combination with Moxifloxacin.]
[N05AF03, chlorprothixene, The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Moxifloxacin.]
[M03BB03, chlorzoxazone, The metabolism of Chlorzoxazone can be decreased when combined with Moxifloxacin.]
[N02BA07, ethenzamide, Ethenzamide may increase the neuroexcitatory activities of Moxifloxacin.]
[M01AB08, etodolac, Etodolac may increase the neuroexcitatory activities of Moxifloxacin.]
[M02AA06, etofenamate, Etofenamate may increase the neuroexcitatory activities of Moxifloxacin.]
[B06AC06, berotralstat, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Berotralstat.]
[L02BX04, relugolix, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Moxifloxacin.]
[N03AX10, felbamate, The risk or severity of QTc prolongation can be increased when Felbamate is combined with Moxifloxacin.]
[M01AE05, fenbufen, Fenbufen may increase the neuroexcitatory activities of Moxifloxacin.]
[N06BA10, fenethylline, The metabolism of Fenethylline can be decreased when combined with Moxifloxacin.]
[V08CA07, ferric ammonium citrate, Ferric ammonium citrate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V03AB31, prussian blue insoluble, Prussian blue can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AB02, iron sucrose, Iron sucrose can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA05, ferrous chloride, Ferrous chloride can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA02, ferrous fumarate, Ferrous fumarate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA03, ferrous gluconate, Ferrous gluconate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA06, ferrous succinate, Ferrous succinate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA07, ferrous sulfate, Ferrous sulfate anhydrous can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Flumequine is combined with Moxifloxacin.]
[R03BA03, flunisolide, The risk or severity of tendinopathy can be increased when Flunisolide is combined with Moxifloxacin.]
[S02BA08, fluocinolone acetonide, The risk or severity of tendinopathy can be increased when Fluocinolone acetonide is combined with Moxifloxacin.]
[R03CC15, formoterol, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Moxifloxacin.]
[A10AF01, insulin, regular, human, The therapeutic efficacy of Insulin human can be increased when used in combination with Moxifloxacin.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Moxifloxacin.]
[B03AB10, ferric maltol, Ferric maltol can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N07CA02, cinnarizine, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Cinnarizine.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Cinoxacin.]
[S03AA07, ciprofloxacin, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Ciprofloxacin.]
[N06AB04, citalopram, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Citalopram.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Moxifloxacin is combined with Fexinidazole.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Mobocertinib.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Clemastine.]
[M01AG01, mefenamic acid, The metabolism of Mefenamic acid can be decreased when combined with Moxifloxacin.]
[A10BB12, glimepiride, The therapeutic efficacy of Glimepiride can be increased when used in combination with Moxifloxacin.]
[A10BB08, gliquidone, The therapeutic efficacy of Gliquidone can be increased when used in combination with Moxifloxacin.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Moxifloxacin.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Moxifloxacin is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The risk or severity of QTc prolongation can be increased when Pacritinib is combined with Moxifloxacin.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be decreased when combined with Moxifloxacin.]
[S01EA04, clonidine, The metabolism of Clonidine can be decreased when combined with Moxifloxacin.]
[A10BX16, tirzepatide, The therapeutic efficacy of Tirzepatide can be increased when used in combination with Moxifloxacin.]
[A04AA01, ondansetron, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Ondansetron.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Granisetron.]
[J01CF02, cloxacillin, The serum concentration of Moxifloxacin can be increased when it is combined with Cloxacillin.]
[N05AH02, clozapine, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Clozapine.]
[A10BX01, guar gum, The therapeutic efficacy of Guar gum can be increased when used in combination with Moxifloxacin.]
[A10BK06, sotagliflozin, The therapeutic efficacy of Sotagliflozin can be increased when used in combination with Moxifloxacin.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Moxifloxacin is combined with Cocaine.]
[M01AX13, proquazone, Proquazone may increase the neuroexcitatory activities of Moxifloxacin.]
[J01CA18, hetacillin, The serum concentration of Moxifloxacin can be increased when it is combined with Hetacillin.]
[L04AA13, leflunomide, The metabolism of Leflunomide can be decreased when combined with Moxifloxacin.]
[A02AD04, hydrotalcite, Hydrotalcite can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N01AB07, desflurane, The risk or severity of QTc prolongation can be increased when Desflurane is combined with Moxifloxacin.]
[A10BX03, nateglinide, The therapeutic efficacy of Nateglinide can be increased when used in combination with Moxifloxacin.]
[N02BA16, imidazole-2-hydroxybenzoate, Imidazole salicylate may increase the neuroexcitatory activities of Moxifloxacin.]
[H01AC03, mecasermin, The therapeutic efficacy of Mecasermin can be increased when used in combination with Moxifloxacin.]
[A10AE04, insulin glargine, The therapeutic efficacy of Insulin glargine can be increased when used in combination with Moxifloxacin.]
[J01FA15, telithromycin, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Telithromycin.]
[R03BA08, ciclesonide, The risk or severity of tendinopathy can be increased when Ciclesonide is combined with Moxifloxacin.]
[B01AC10, indobufen, Indobufen may increase the neuroexcitatory activities of Moxifloxacin.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Desloratadine.]
[M01AH03, valdecoxib, Valdecoxib may increase the neuroexcitatory activities of Moxifloxacin.]
[M01AH04, parecoxib, Parecoxib may increase the neuroexcitatory activities of Moxifloxacin.]
[J02AC02, itraconazole, The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Moxifloxacin.]
[S01AD03, acyclovir, The metabolism of Acyclovir can be decreased when combined with Moxifloxacin.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Emedastine.]
[M01AA06, kebuzone, Kebuzone may increase the neuroexcitatory activities of Moxifloxacin.]
[L01EA01, imatinib, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Imatinib.]
[J02AC04, posaconazole, The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Moxifloxacin.]
[C08CA09, lacidipine, The risk or severity of QTc prolongation can be increased when Lacidipine is combined with Moxifloxacin.]
[N03AX09, lamotrigine, The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Moxifloxacin.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Moxifloxacin.]
[S01BA03, cortisone, The risk or severity of tendinopathy can be increased when Cortisone is combined with Moxifloxacin.]
[N07BC04, lofexidine, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Lofexidine.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Lomefloxacin.]
[M01AB09, lonazolac, Lonazolac may increase the neuroexcitatory activities of Moxifloxacin.]
[M02AA31, loxoprofen, Loxoprofen may increase the neuroexcitatory activities of Moxifloxacin.]
[A02AD02, magaldrate, Magaldrate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A06AD01, magnesium carbonate, Magnesium carbonate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[H02AB15, meprednisone, The risk or severity of tendinopathy can be increased when Meprednisone is combined with Moxifloxacin.]
[R06AD07, mequitazine, The risk or severity of QTc prolongation can be increased when Mequitazine is combined with Moxifloxacin.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Adenosine.]
[J01CA14, methampicillin, The serum concentration of Moxifloxacin can be increased when it is combined with Metampicillin.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Moxifloxacin.]
[N05AD03, metylperon, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Melperone.]
[A10BF02, miglitol, The therapeutic efficacy of Miglitol can be increased when used in combination with Moxifloxacin.]
[S01XA18, cyclosporine, The risk or severity of nephrotoxicity can be increased when Moxifloxacin is combined with Cyclosporine.]
[R06AX02, cyproheptadine, The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Moxifloxacin.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Moxifloxacin.]
[M02AA02, mofebutazone, Mofebutazone may increase the neuroexcitatory activities of Moxifloxacin.]
[M01AX22, morniflumate, Morniflumate may increase the neuroexcitatory activities of Moxifloxacin.]
[J05AF10, entecavir, The metabolism of Entecavir can be decreased when combined with Moxifloxacin.]
[G04BE09, vardenafil, The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Moxifloxacin.]
[M01AH05, etoricoxib, The metabolism of Etoricoxib can be decreased when combined with Moxifloxacin.]
[L01AX04, dacarbazine, The metabolism of Dacarbazine can be decreased when combined with Moxifloxacin.]
[M01AX01, nabumetone, The metabolism of Nabumetone can be decreased when combined with Moxifloxacin.]
[C01CA23, theodrenaline, The metabolism of Theodrenaline can be decreased when combined with Moxifloxacin.]
[M03AC11, cisatracurium, Moxifloxacin may increase the neuromuscular blocking activities of Cisatracurium.]
[N06AB10, escitalopram, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Escitalopram.]
[G04BD08, solifenacin, The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Moxifloxacin.]
[A07EC03, olsalazine, Olsalazine may increase the neuroexcitatory activities of Moxifloxacin.]
[N06AA01, desipramine, The risk or severity of QTc prolongation can be increased when Desipramine is combined with Moxifloxacin.]
[D07XC02, desoximetasone, The risk or severity of tendinopathy can be increased when Desoximetasone is combined with Moxifloxacin.]
[H02AA03, desoxycorticosterone, The risk or severity of tendinopathy can be increased when Desoxycortone is combined with Moxifloxacin.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Oxaliplatin.]
[M01AE12, oxaprozin, Oxaprozin may increase the neuroexcitatory activities of Moxifloxacin.]
[S03BA01, dexamethasone, The risk or severity of tendinopathy can be increased when Dexamethasone is combined with Moxifloxacin.]
[A08AA04, dexfenfluramine, The metabolism of Dexfenfluramine can be decreased when combined with Moxifloxacin.]
[N06AB05, paroxetine, The metabolism of Paroxetine can be decreased when combined with Moxifloxacin.]
[B01AC04, clopidogrel, The metabolism of Clopidogrel can be decreased when combined with Moxifloxacin.]
[C04AD01, pentifylline, The metabolism of Pentifylline can be decreased when combined with Moxifloxacin.]
[J01CE05, phenethicillin, The serum concentration of Moxifloxacin can be increased when it is combined with Pheneticillin.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Moxifloxacin is combined with Phenol.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Moxifloxacin is combined with Cinchocaine.]
[S01BC03, diclofenac, The metabolism of Diclofenac can be decreased when combined with Moxifloxacin.]
[J01CF01, dicloxacillin, The serum concentration of Moxifloxacin can be increased when it is combined with Dicloxacillin.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Moxifloxacin.]
[J05AF02, didanosine, Didanosine can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A03AX04, pinaverium, The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Moxifloxacin.]
[A10BG03, pioglitazone, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Moxifloxacin.]
[L01EB02, erlotinib, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Erlotinib.]
[C08CA03, isradipine, The risk or severity of QTc prolongation can be increased when Isradipine is combined with Moxifloxacin.]
[D07XC04, diflucortolone, The risk or severity of tendinopathy can be increased when Difluocortolone is combined with Moxifloxacin.]
[N02BA11, diflunisal, Diflunisal may increase the neuroexcitatory activities of Moxifloxacin.]
[C01AA04, digitoxin, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Moxifloxacin.]
[C01AA05, digoxin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Moxifloxacin.]
[C02DB01, dihydralazine, The metabolism of Dihydralazine can be decreased when combined with Moxifloxacin.]
[J05AE08, atazanavir, The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Moxifloxacin.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Moxifloxacin.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Moxifloxacin is combined with Pramocaine.]
[C08DB01, diltiazem, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Dimenhydrinate.]
[N06BC02, propentofylline, The metabolism of Propentofylline can be decreased when combined with Moxifloxacin.]
[J01CE03, propicillin, The serum concentration of Moxifloxacin can be increased when it is combined with Propicillin.]
[N02BB04, propyphenazone, Propyphenazone may increase the neuroexcitatory activities of Moxifloxacin.]
[M01AB14, proglumetacin, Proglumetacin may increase the neuroexcitatory activities of Moxifloxacin.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Moxifloxacin is combined with Proparacaine.]
[R03DA03, proxyphylline, The metabolism of Proxyphylline can be decreased when combined with Moxifloxacin.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Moxifloxacin is combined with Diphenhydramine.]
[C09AA06, quinapril, Quinapril can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A03FA02, cisapride, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Cisapride.]
[C01BA03, disopyramide, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Disopyramide.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Moxifloxacin.]
[N07XX02, riluzole, The metabolism of Riluzole can be decreased when combined with Moxifloxacin.]
[N05AX08, risperidone, The risk or severity of QTc prolongation can be increased when Risperidone is combined with Moxifloxacin.]
[R06AE09, levocetirizine, The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Moxifloxacin.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Moxifloxacin is combined with Ropivacaine.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Moxifloxacin.]
[L01EX01, sunitinib, The therapeutic efficacy of Sunitinib can be increased when used in combination with Moxifloxacin.]
[L01XG01, bortezomib, The metabolism of Bortezomib can be decreased when combined with Moxifloxacin.]
[S01BC05, ketorolac, Ketorolac may increase the neuroexcitatory activities of Moxifloxacin.]
[C01EB18, ranolazine, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Ranolazine.]
[N02BA06, salsalate, Salsalate may increase the neuroexcitatory activities of Moxifloxacin.]
[R03AC12, salmeterol, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Moxifloxacin.]
[A03FA03, domperidone, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Domperidone.]
[N06AA16, dothiepin, The risk or severity of QTc prolongation can be increased when Dosulepin is combined with Moxifloxacin.]
[N06AA12, doxepin, The metabolism of Doxepin can be decreased when combined with Moxifloxacin.]
[R06AA09, doxylamine, The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Moxifloxacin.]
[N01AB08, sevoflurane, The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Moxifloxacin.]
[N05AD08, droperidol, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Droperidol.]
[R03DA01, dyphylline, The metabolism of Dyphylline can be decreased when combined with Moxifloxacin.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Sultopride.]
[C07AB13, talinolol, The risk or severity of QTc prolongation can be increased when Talinolol is combined with Moxifloxacin.]
[H01AA01, corticotropin, The risk or severity of tendinopathy can be increased when Corticotropin is combined with Moxifloxacin.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Temafloxacin.]
[J01CA17, temocillin, The serum concentration of Moxifloxacin can be increased when it is combined with Temocillin.]
[M01AC02, tenoxicam, Tenoxicam may increase the neuroexcitatory activities of Moxifloxacin.]
[D01BA02, terbinafine, The metabolism of Terbinafine can be decreased when combined with Moxifloxacin.]
[G04BD05, terodiline, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Terodiline.]
[M01AG02, tolfenamic acid, Tolfenamic acid may increase the neuroexcitatory activities of Moxifloxacin.]
[N06BA09, atomoxetine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Moxifloxacin.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Toremifene.]
[H02CA01, trilostane, The risk or severity of tendinopathy can be increased when Trilostane is combined with Moxifloxacin.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Moxifloxacin.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Moxifloxacin.]
[S01GX10, epinastine, The risk or severity of QTc prolongation can be increased when Epinastine is combined with Moxifloxacin.]
[B05XA12, zinc chloride, Zinc chloride can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B05XA18, zinc sulfate, Zinc sulfate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N05CF02, zolpidem, The metabolism of Zolpidem can be decreased when combined with Moxifloxacin.]
[M01AB04, zomepirac, Zomepirac may increase the neuroexcitatory activities of Moxifloxacin.]
[N03AX15, zonisamide, The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Moxifloxacin.]
[A10AB06, insulin glulisine, human, The therapeutic efficacy of Insulin glulisine can be increased when used in combination with Moxifloxacin.]
[N05AX11, zotepine, The metabolism of Zotepine can be decreased when combined with Moxifloxacin.]
[C01BG01, moricizine, The risk or severity of QTc prolongation can be increased when Moricizine is combined with Moxifloxacin.]
[S01AA17, erythromycin, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Moxifloxacin.]
[H05BX01, cinacalcet, The metabolism of Cinacalcet can be decreased when combined with Moxifloxacin.]
[G03CA03, estradiol, The metabolism of Estradiol can be decreased when combined with Moxifloxacin.]
[G03CA57, estrogens, conjugated (USP), The metabolism of Conjugated estrogens can be decreased when combined with Moxifloxacin.]
[R03BA09, fluticasone furoate, The risk or severity of tendinopathy can be increased when Fluticasone furoate is combined with Moxifloxacin.]
[R03BA05, fluticasone, The risk or severity of tendinopathy can be increased when Fluticasone is combined with Moxifloxacin.]
[L02AA03, ethinyl estradiol, The metabolism of Ethinylestradiol can be decreased when combined with Moxifloxacin.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Ibutilide.]
[N03AD01, ethosuximide, The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Moxifloxacin.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Moxifloxacin is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Moxifloxacin is combined with Meloxicam.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Moxifloxacin is combined with Etidocaine.]
[L01CB01, etoposide, The metabolism of Etoposide can be decreased when combined with Moxifloxacin.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Moxifloxacin.]
[L04AD02, tacrolimus, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Moxifloxacin.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Moxifloxacin.]
[R06AX11, astemizole, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Astemizole.]
[R06AX12, terfenadine, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Terfenadine.]
[N06AB08, fluvoxamine, The metabolism of Fluvoxamine can be decreased when combined with Moxifloxacin.]
[C01BB03, tocainide, The metabolism of Tocainide can be decreased when combined with Moxifloxacin.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Encainide is combined with Moxifloxacin.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Moxifloxacin.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Moxifloxacin.]
[P02CA03, albendazole, The metabolism of Albendazole can be decreased when combined with Moxifloxacin.]
[C08CA02, felodipine, The risk or severity of QTc prolongation can be increased when Felodipine is combined with Moxifloxacin.]
[C08EA01, fendiline, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Fendiline.]
[N03AX26, fenfluramine, The metabolism of Fenfluramine can be decreased when combined with Moxifloxacin.]
[M01AE04, fenoprofen, Fenoprofen may increase the neuroexcitatory activities of Moxifloxacin.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Moxifloxacin.]
[C01BC04, flecainide, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Flecainide.]
[N02BG04, floctafenine, Floctafenine may increase the neuroexcitatory activities of Moxifloxacin.]
[J01CF05, floxacillin, The serum concentration of Moxifloxacin can be increased when it is combined with Flucloxacillin.]
[J02AC01, fluconazole, The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Moxifloxacin.]
[H02AA02, fludrocortisone, The risk or severity of tendinopathy can be increased when Fludrocortisone is combined with Moxifloxacin.]
[D07XB01, flumethasone, The risk or severity of tendinopathy can be increased when Flumethasone is combined with Moxifloxacin.]
[N07CA03, flunarizine, The metabolism of Flunarizine can be decreased when combined with Moxifloxacin.]
[D07AC08, fluocinonide, The risk or severity of tendinopathy can be increased when Fluocinonide is combined with Moxifloxacin.]
[H02AB03, fluocortolone, The risk or severity of tendinopathy can be increased when Fluocortolone is combined with Moxifloxacin.]
[V03AZ01, ethanol, The metabolism of Ethanol can be decreased when combined with Moxifloxacin.]
[L01BC02, fluorouracil, The metabolism of Fluorouracil can be decreased when combined with Moxifloxacin.]
[N06AB03, fluoxetine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Moxifloxacin.]
[N05AF01, flupenthixol, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Flupentixol.]
[S01BC04, flurbiprofen, Flurbiprofen may increase the neuroexcitatory activities of Moxifloxacin.]
[N05AG01, fluspirilene, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Fluspirilene.]
[L02BB01, flutamide, The metabolism of Flutamide can be decreased when combined with Moxifloxacin.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Moxifloxacin.]
[N05AL05, amisulpride, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Amisulpride.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Moxifloxacin.]
[C08DA02, gallopamil, The risk or severity of QTc prolongation can be increased when Gallopamil is combined with Moxifloxacin.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Telavancin.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Degarelix is combined with Moxifloxacin.]
[L01EA02, dasatinib, The metabolism of Dasatinib can be decreased when combined with Moxifloxacin.]
[C01CA21, cafedrine, The metabolism of Cafedrine can be decreased when combined with Moxifloxacin.]
[A10BJ02, liraglutide, The therapeutic efficacy of Liraglutide can be increased when used in combination with Moxifloxacin.]
[N03AD03, methsuximide, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Moxifloxacin.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Moxifloxacin.]
[A10BB01, glyburide, The therapeutic efficacy of Glyburide can be increased when used in combination with Moxifloxacin.]
[A10BB09, gliclazide, The therapeutic efficacy of Gliclazide can be increased when used in combination with Moxifloxacin.]
[A10BB07, glipizide, The therapeutic efficacy of Glipizide can be increased when used in combination with Moxifloxacin.]
[C01BD04, dofetilide, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Dofetilide.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be decreased when combined with Moxifloxacin.]
[C07AB09, esmolol, The risk or severity of QTc prolongation can be increased when Esmolol is combined with Moxifloxacin.]
[B01AA12, fluindione, The therapeutic efficacy of Fluindione can be increased when used in combination with Moxifloxacin.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Goserelin is combined with Moxifloxacin.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Haloperidol.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Histrelin is combined with Moxifloxacin.]
[N05AH04, quetiapine, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Quetiapine.]
[A10AD05, insulin aspart, human, The therapeutic efficacy of Insulin aspart can be increased when used in combination with Moxifloxacin.]
[C09CA01, losartan, The risk or severity of QTc prolongation can be increased when Losartan is combined with Moxifloxacin.]
[B05CB03, magnesium citrate, Magnesium citrate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A12CC03, magnesium gluconate, Magnesium gluconate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A07EC02, mesalamine, Mesalazine may increase the neuroexcitatory activities of Moxifloxacin.]
[C08CA10, nilvadipine, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Nilvadipine.]
[M02AA26, nimesulide, Nimesulide may increase the neuroexcitatory activities of Moxifloxacin.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Oxatomide.]
[C03AA03, hydrochlorothiazide, The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Moxifloxacin.]
[S02BA01, hydrocortisone, The risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Moxifloxacin.]
[P01BA02, hydroxychloroquine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Moxifloxacin.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Hydroxyzine.]
[R02AX02, ibuprofen, Ibuprofen may increase the neuroexcitatory activities of Moxifloxacin.]
[N06AA02, imipramine, The metabolism of Imipramine can be decreased when combined with Moxifloxacin.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Terlipressin.]
[R01AD07, tixocortol, The risk or severity of tendinopathy can be increased when Tixocortol is combined with Moxifloxacin.]
[M03BX02, tizanidine, The serum concentration of Tizanidine can be increased when it is combined with Moxifloxacin.]
[C03BA11, indapamide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Moxifloxacin.]
[S01BC01, indomethacin, Indomethacin may increase the neuroexcitatory activities of Moxifloxacin.]
[A16AX05, zinc acetate, Zinc acetate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A12CB02, zinc gluconate, Zinc gluconate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Moxifloxacin is combined with Articaine.]
[A10BH01, sitagliptin, The therapeutic efficacy of Sitagliptin can be increased when used in combination with Moxifloxacin.]
[N05CH02, ramelteon, The metabolism of Ramelteon can be decreased when combined with Moxifloxacin.]
[R06AE01, buclizine, The risk or severity of QTc prolongation can be increased when Buclizine is combined with Moxifloxacin.]
[A10BH02, vildagliptin, The therapeutic efficacy of Vildagliptin can be increased when used in combination with Moxifloxacin.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Anagrelide.]
[J05AB13, penciclovir, The metabolism of Penciclovir can be decreased when combined with Moxifloxacin.]
[N01AB06, isoflurane, The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Moxifloxacin.]
[A10BJ01, exenatide, The therapeutic efficacy of Exenatide can be increased when used in combination with Moxifloxacin.]
[A02AB01, aluminum hydroxide, Aluminum hydroxide can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J02AB02, ketoconazole, The risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Moxifloxacin.]
[N05AH03, olanzapine, The metabolism of Olanzapine can be decreased when combined with Moxifloxacin.]
[M02AA10, ketoprofen, Ketoprofen may increase the neuroexcitatory activities of Moxifloxacin.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Mizolastine.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Nalidixic acid.]
[M01AE11, tiaprofenic acid, Tiaprofenic acid may increase the neuroexcitatory activities of Moxifloxacin.]
[N04BB01, amantadine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Moxifloxacin.]
[A06AD11, lactulose, The therapeutic efficacy of Lactulose can be decreased when used in combination with Moxifloxacin.]
[J01CA11, amdinocillin, The serum concentration of Moxifloxacin can be increased when it is combined with Amdinocillin.]
[J01CA08, amdinocillin pivoxil, The serum concentration of Moxifloxacin can be increased when it is combined with Pivmecillinam.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Moxifloxacin is combined with Lidocaine.]
[C08EX01, lidoflazine, The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Moxifloxacin.]
[A07DA03, loperamide, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Loperamide.]
[B05XA11, magnesium chloride, Magnesium chloride can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[G04BX01, magnesium hydroxide, Magnesium hydroxide can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A12CC10, magnesium oxide, Magnesium oxide can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V04CC02, magnesium sulfate, Magnesium sulfate can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01EA03, nilotinib, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Nilotinib.]
[N06AA21, maprotiline, The metabolism of Maprotiline can be decreased when combined with Moxifloxacin.]
[M02AA18, meclofenamic acid, Meclofenamic acid may increase the neuroexcitatory activities of Moxifloxacin.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Moxifloxacin.]
[N05CH01, melatonin, The metabolism of Melatonin can be decreased when combined with Moxifloxacin.]
[N03AB04, mephenytoin, The metabolism of Mephenytoin can be decreased when combined with Moxifloxacin.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Moxifloxacin is combined with Mepivacaine.]
[N05AC03, mesoridazine, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Mesoridazine.]
[N05AX13, paliperidone, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Paliperidone.]
[A10BA02, metformin, The therapeutic efficacy of Metformin can be increased when used in combination with Moxifloxacin.]
[A04AA04, dolasetron, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Dolasetron.]
[N07BC02, methadone, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Methadone.]
[L01BA04, pemetrexed, The metabolism of Pemetrexed can be decreased when combined with Moxifloxacin.]
[N05AA02, methotrimeprazine, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Moxifloxacin.]
[V04CG05, methylene blue, The metabolism of Methylene blue can be decreased when combined with Moxifloxacin.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be decreased when combined with Moxifloxacin.]
[H02AB04, methylprednisolone, The risk or severity of tendinopathy can be increased when Methylprednisolone is combined with Moxifloxacin.]
[D07AC14, methylprednisolone aceponate, The risk or severity of tendinopathy can be increased when Methylprednisolone aceponate is combined with Moxifloxacin.]
[A03FA01, metoclopramide, The metabolism of Metoclopramide can be decreased when combined with Moxifloxacin.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Moxifloxacin.]
[C01BB02, mexiletine, The metabolism of Mexiletine can be decreased when combined with Moxifloxacin.]
[J01CA10, mezlocillin, The serum concentration of Moxifloxacin can be increased when it is combined with Mezlocillin.]
[N06AX03, mianserin, The metabolism of Mianserin can be decreased when combined with Moxifloxacin.]
[N02BB03, aminopyrine, The metabolism of Aminophenazone can be decreased when combined with Moxifloxacin.]
[G03XB01, mifepristone, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Mifepristone.]
[C01BD01, amiodarone, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Amiodarone.]
[N06AA09, amitriptyline, Moxifloxacin may increase the QTc-prolonging activities of Amitriptyline.]
[B02BX05, eltrombopag, The metabolism of Eltrombopag can be decreased when combined with Moxifloxacin.]
[L01EX03, pazopanib, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Pazopanib.]
[L04AA06, mycophenolic acid, The serum concentration of Mycophenolic acid can be decreased when it is combined with Moxifloxacin.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Moxifloxacin.]
[N06AA17, amoxapine, The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Moxifloxacin.]
[J01CA04, amoxicillin, The serum concentration of Moxifloxacin can be increased when it is combined with Amoxicillin.]
[N04BC04, ropinirole, The risk or severity of adverse effects can be increased when Moxifloxacin is combined with Ropinirole.]
[J01CF06, nafcillin, The serum concentration of Moxifloxacin can be increased when it is combined with Nafcillin.]
[M02AA12, naproxen, The metabolism of Naproxen can be decreased when combined with Moxifloxacin.]
[A10BG01, troglitazone, The therapeutic efficacy of Troglitazone can be increased when used in combination with Moxifloxacin.]
[A10BX02, repaglinide, The therapeutic efficacy of Repaglinide can be increased when used in combination with Moxifloxacin.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Levosimendan.]
[N05AX14, iloperidone, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Iloperidone.]
[S01AA19, ampicillin, The serum concentration of Moxifloxacin can be increased when it is combined with Ampicillin.]
[C08CA04, nicardipine, The risk or severity of QTc prolongation can be increased when Nicardipine is combined with Moxifloxacin.]
[C08CA05, nifedipine, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Nifedipine.]
[M02AA17, niflumic acid, Niflumic acid may increase the neuroexcitatory activities of Moxifloxacin.]
[C08CA06, nimodipine, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Nimodipine.]
[C08CA08, nitrendipine, The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Moxifloxacin.]
[J01XE01, nitrofurantoin, The therapeutic efficacy of Moxifloxacin can be decreased when used in combination with Nitrofurantoin.]
[C02DD01, nitroprusside, Nitroprusside can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Moxifloxacin.]
[N06AA10, nortriptyline, The risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Moxifloxacin.]
[H01CB02, octreotide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Moxifloxacin.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Ofloxacin.]
[J01CF04, oxacillin, The serum concentration of Moxifloxacin can be increased when it is combined with Oxacillin.]
[V08CB01, ferumoxsil, Ferumoxsil can cause a decrease in the absorption of Moxifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Moxifloxacin.]
[S01BC02, oxyphenbutazone, Oxyphenbutazone may increase the neuroexcitatory activities of Moxifloxacin.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Moxifloxacin.]
[N05AH05, asenapine, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Asenapine.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Papaverine.]
[H02AB05, paramethasone, The risk or severity of tendinopathy can be increased when Paramethasone is combined with Moxifloxacin.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Moxifloxacin.]
[N05AG03, penfluridol, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Penfluridol.]
[S01AA14, penicillin G, The serum concentration of Moxifloxacin can be increased when it is combined with Benzylpenicillin.]
[J01CE09, penicillin G procaine, The serum concentration of Moxifloxacin can be increased when it is combined with Procaine benzylpenicillin.]
[J01CE02, penicillin V, The serum concentration of Moxifloxacin can be increased when it is combined with Phenoxymethylpenicillin.]
[C04AD03, pentoxifylline, The metabolism of Pentoxifylline can be decreased when combined with Moxifloxacin.]
[C08EX02, perhexiline, The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Moxifloxacin.]
[N05AB03, perphenazine, The metabolism of Perphenazine can be decreased when combined with Moxifloxacin.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Moxifloxacin.]
[A10BA01, phenformin, The therapeutic efficacy of Phenformin can be increased when used in combination with Moxifloxacin.]
[B01AA02, phenindione, The therapeutic efficacy of Phenindione can be increased when used in combination with Moxifloxacin.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Moxifloxacin.]
[B01AA04, phenprocoumon, The therapeutic efficacy of Phenprocoumon can be increased when used in combination with Moxifloxacin.]
[M02AA01, phenylbutazone, Phenylbutazone may increase the neuroexcitatory activities of Moxifloxacin.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Levofloxacin.]
[C08CX01, mibefradil, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Mibefradil.]
[N05AG02, pimozide, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Pimozide.]
[J01CA12, piperacillin, The serum concentration of Moxifloxacin can be increased when it is combined with Piperacillin.]
[J05AE01, saquinavir, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Saquinavir.]
[S01BC06, piroxicam, Piroxicam may increase the neuroexcitatory activities of Moxifloxacin.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Grepafloxacin.]
[J01CA02, pivampicillin, The serum concentration of Moxifloxacin can be increased when it is combined with Pivampicillin.]
[A10BG02, rosiglitazone, The therapeutic efficacy of Rosiglitazone can be increased when used in combination with Moxifloxacin.]
[A03AE01, alosetron, The metabolism of Alosetron can be decreased when combined with Moxifloxacin.]
[J05AE03, ritonavir, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Moxifloxacin.]
[A10BH03, saxagliptin, The therapeutic efficacy of Saxagliptin can be increased when used in combination with Moxifloxacin.]
[A10AD04, insulin lispro, The therapeutic efficacy of Insulin lispro can be increased when used in combination with Moxifloxacin.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Prajmaline is combined with Moxifloxacin.]
[P02BA01, praziquantel, The metabolism of Praziquantel can be decreased when combined with Moxifloxacin.]
[S03BA02, prednisolone, The risk or severity of tendinopathy can be increased when Prednisolone is combined with Moxifloxacin.]
[H02AB07, prednisone, The risk or severity of tendinopathy can be increased when Prednisone is combined with Moxifloxacin.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Antazoline.]
[C01DX02, prenylamine, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Prenylamine.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Moxifloxacin is combined with Prilocaine.]
[P01BA03, primaquine, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Primaquine.]
[M04AB01, probenecid, Probenecid may decrease the excretion rate of Moxifloxacin which could result in a higher serum level.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Probucol.]
[C01BA02, procainamide, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Procainamide.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Moxifloxacin is combined with Procaine.]
[N05AB04, prochlorperazine, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Prochlorperazine.]
[N05AA03, promazine, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Promazine.]
[R06AD02, promethazine, The risk or severity of QTc prolongation can be increased when Promethazine is combined with Moxifloxacin.]
[C01BC03, propafenone, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Propafenone.]
[L01XH02, romidepsin, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Romidepsin.]
[N01AX10, propofol, The risk or severity of QTc prolongation can be increased when Propofol is combined with Moxifloxacin.]
[C07AA05, propranolol, The metabolism of Propranolol can be decreased when combined with Moxifloxacin.]
[N06AA11, protriptyline, The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Moxifloxacin.]
[N05AX12, aripiprazole, The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Moxifloxacin.]
[R06AC01, pyrilamine, The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Moxifloxacin.]
[C01BA01, quinidine, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Quinidine.]
[P01BC01, quinine, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Quinine.]
[A02BA02, ranitidine, The metabolism of Ranitidine can be decreased when combined with Moxifloxacin.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Roxithromycin.]
[N02BA05, salicylamide, Salicylamide may increase the neuroexcitatory activities of Moxifloxacin.]
[A07EC01, sulfasalazine, Sulfasalazine may increase the neuroexcitatory activities of Moxifloxacin.]
[S01BC08, salicylic acid, Salicylic acid may increase the neuroexcitatory activities of Moxifloxacin.]
[N04BD01, selegiline, The metabolism of Selegiline can be decreased when combined with Moxifloxacin.]
[C07AA07, sotalol, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Sotalol.]
[N03AG01, valproic acid, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Valproic acid.]
[D07AB02, hydrocortisone butyrate, The risk or severity of tendinopathy can be increased when Hydrocortisone butyrate is combined with Moxifloxacin.]
[N05AL01, sulpiride, QT prolonging agents - QT prolonging agents]
[N05AC02, thioridazine, QT prolonging agents - QT prolonging agents]
[L01EX04, vandetanib, QT prolonging agents - QT prolonging agents]
[N06DA02, donepezil, QT prolonging agents - QT prolonging agents]
[C08EA02, bepridil, QT prolonging agents - QT prolonging agents]
[L01XX27, arsenic trioxide, QT prolonging agents - QT prolonging agents]
[J01MA09, sparfloxacin, QT prolonging agents - QT prolonging agents]
[S01AA26, azithromycin, QT prolonging agents - QT prolonging agents]
[B01AC23, cilostazol, QT prolonging agents - QT prolonging agents]
[J01FA09, clarithromycin, QT prolonging agents - QT prolonging agents]
[S01AE06, gatifloxacin, QT prolonging agents - QT prolonging agents]
[C01BD07, dronedarone, QT prolonging agents - QT prolonging agents]
[L01DB04, aclarubicin, QT prolonging agents - QT prolonging agents]
[P01BA01, chloroquine, QT prolonging agents - QT prolonging agents]
[N05AA01, chlorpromazine, QT prolonging agents - QT prolonging agents]
[N05AF03, chlorprothixene, QT prolonging agents - QT prolonging agents]
[S03AA07, ciprofloxacin, QT prolonging agents - QT prolonging agents]
[N06AB04, citalopram, QT prolonging agents - QT prolonging agents]
[L01EB10, mobocertinib, QT prolonging agents - QT prolonging agents]
[A04AA01, ondansetron, QT prolonging agents - QT prolonging agents]
[S02DA02, cocaine, QT prolonging agents - QT prolonging agents]
[C01BA13, hydroquinidine, QT prolonging agents - QT prolonging agents]
[P01CB01, meglumine antimoniate, QT prolonging agents - QT prolonging agents]
[L01XA03, oxaliplatin, QT prolonging agents - QT prolonging agents]
[A03FA02, cisapride, QT prolonging agents - QT prolonging agents]
[C01BA03, disopyramide, QT prolonging agents - QT prolonging agents]
[A03FA03, domperidone, QT prolonging agents - QT prolonging agents]
[N01AB08, sevoflurane, QT prolonging agents - QT prolonging agents]
[N05AD08, droperidol, QT prolonging agents - QT prolonging agents]
[N05AL02, sultopride, QT prolonging agents - QT prolonging agents]
[G04BD05, terodiline, QT prolonging agents - QT prolonging agents]
[S01AA17, erythromycin, QT prolonging agents - QT prolonging agents]
[C01BD05, ibutilide, QT prolonging agents - QT prolonging agents]
[N05AE03, sertindole, QT prolonging agents - QT prolonging agents]
[R06AX11, astemizole, QT prolonging agents - QT prolonging agents]
[R06AX12, terfenadine, QT prolonging agents - QT prolonging agents]
[C01BC04, flecainide, QT prolonging agents - QT prolonging agents]
[J02AC01, fluconazole, QT prolonging agents - QT prolonging agents]
[C01BD04, dofetilide, QT prolonging agents - QT prolonging agents]
[P01BX01, halofantrine, QT prolonging agents - QT prolonging agents]
[N05AD01, haloperidol, QT prolonging agents - QT prolonging agents]
[P01BA02, hydroxychloroquine, QT prolonging agents - QT prolonging agents]
[H01BA04, terlipressin, QT prolonging agents - QT prolonging agents]
[L01XX35, anagrelide, QT prolonging agents - QT prolonging agents]
[N05AC03, mesoridazine, QT prolonging agents - QT prolonging agents]
[N07BC02, methadone, QT prolonging agents - QT prolonging agents]
[N05AA02, methotrimeprazine, QT prolonging agents - QT prolonging agents]
[C01BD01, amiodarone, QT prolonging agents - QT prolonging agents]
[S01AE05, levofloxacin, QT prolonging agents - QT prolonging agents]
[N05AG02, pimozide, QT prolonging agents - QT prolonging agents]
[J01MA11, grepafloxacin, QT prolonging agents - QT prolonging agents]
[C10AX02, probucol, QT prolonging agents - QT prolonging agents]
[C01BA02, procainamide, QT prolonging agents - QT prolonging agents]
[N01AX10, propofol, QT prolonging agents - QT prolonging agents]
[C01BA01, quinidine, QT prolonging agents - QT prolonging agents]
[J01FA06, roxithromycin, QT prolonging agents - QT prolonging agents]
[C07AA07, sotalol, QT prolonging agents - QT prolonging agents]
